These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39418085)

  • 21. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
    Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
    Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
    Stefanou MI; Theodorou A; Malhotra K; Aguiar de Sousa D; Katan M; Palaiodimou L; Katsanos AH; Koutroulou I; Lambadiari V; Lemmens R; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G
    Eur Stroke J; 2024 Sep; 9(3):530-539. PubMed ID: 38400569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
    Ghazanfar H; Javed N; Qasim A; Sosa F; Altaf F; Khan S; Mahasamudram J; Jyala A; Kandhi SD; Shin D; Mantri N; Sun H; Hanumanthu S; Patel H; Makker J; Balar B; Dev A; Chilimuri S
    World J Gastroenterol; 2024 Jul; 30(26):3221-3228. PubMed ID: 39086638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.
    Kalas MA; Dang TQ; Galura G; Alvarado L; Dwivedi AK; Deoker A; McCallum R
    J Investig Med; 2023 Jan; 71(1):11-16. PubMed ID: 36198436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards.
    Horowitz M; Cai L; Islam MS
    World J Diabetes; 2024 Mar; 15(3):326-330. PubMed ID: 38591090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
    Nauck MA; Kemmeries G; Holst JJ; Meier JJ
    Diabetes; 2011 May; 60(5):1561-5. PubMed ID: 21430088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.
    Al Sakka Amini R; Ismail AS; Al-Aqrabawi M; Aleyadeh W; Mohammed A; Altork N; Abosheaishaa H; Elfert KA; Goble SR; Sawaf B; Chandan S
    Cureus; 2024 Aug; 16(8):e66311. PubMed ID: 39238749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans.
    Wu T; Zhao BR; Bound MJ; Checklin HL; Bellon M; Little TJ; Young RL; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2012 Jan; 95(1):78-83. PubMed ID: 22158727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.
    Psaltis JP; Marathe JA; Nguyen MT; Le R; Bursill CA; Marathe CS; Nelson AJ; Psaltis PJ
    Med Res Rev; 2024 Aug; ():. PubMed ID: 39139038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes.
    Suganuma Y; Shimizu T; Sato T; Morii T; Fujita H; Harada Sassa M; Yamada Y
    J Diabetes Investig; 2020 Mar; 11(2):389-399. PubMed ID: 31301103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: A systematic review & meta-analysis.
    Singh S; Rahman SH; Khan N; Rajagopal A; Shafique N; Tawde P; Bhardwaj V; Suresh Kumar VC; Aswath G; Inamdar S; Dutta S; Hurairah A; Mohan BP
    Gastrointest Endosc; 2024 Oct; ():. PubMed ID: 39401599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
    Maselli DB; Lee D; Bi D; Jirapinyo P; Thompson CC; Donnangelo LL; McGowan CE
    Obes Surg; 2024 Jul; 34(7):2369-2374. PubMed ID: 38753265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.